CAMBRIDGE, Mass., May 19, 2021 /PRNewswire/ — Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies for rare and severe genetic diseases, today announced the appointment of Gopi Shanker, Ph.D., as Chief Scientific Officer and as a member of the company’s executive leadership team. With more than 20 years of experience in industry and academic research, Dr. Shanker will be responsible for advancing Tevard’s preclinical tRNA gene therapy programs into the clinic, for expanding the company’s research into new therapeutic areas, and for directing the company’s preclinical scientific programs and team.
Back to News